Seeking Alpha

Threshold Pharmaceuticals (THLD) receives funding to begin phase 1 trials for its hypoxia...

Threshold Pharmaceuticals (THLD) receives funding to begin phase 1 trials for its hypoxia activated prodrug TH-302. The study will determine the safety and effectiveness of using TH-302 in combination with Glaxo's (GSK) Votrient in advanced solid tumors. THLD shares +2.4% premarket.
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs